Allogeneic Hematopoietic Stem Cell Transplant for Adults over 40 Years Old with Acquired Aplastic Anemia

Hawk Kim, Kyoo Hyung Lee, Sung Soo Yoon, Sang Kyun Sohn, Young Don Joo, Sung Hyun Kim, Byung Soo Kim, Jung Hye Choi, Jae Youg Kwak, Myung Soo Hyun, Sung Hwa Bae, Ho Jin Shin, Jong Ho Won, Sukjoong Oh, Won Sik Lee, Jae Hoo Park, Chul Won Jung

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Although younger age is associated with favorable prognosis in adults undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) for aplastic anemia (AA), other pretransplantation factors may be more important than age. We retrospectively analyzed the impact of older age on transplantation outcomes and survival in a total of 225 adult patients with AA who underwent allo-HSCT: 57 patients >40 years old (older patient group [OPG]) and 168 patients ≤40 years old (younger patient group [YPG]). Age at allo-HSCT ≤40 years, time from diagnosis to allo-HSCT ≤6 months, and matched related donor (MRD) were favorable prognostic factors in all study patients. Risk analysis of survival in the OPG showed that age >50 years was the only poor prognostic factor. Survival did not differ significantly between the YPG and patients <50 years old in the OPG. In conclusion, patients between the ages of 41 and 50 years with severe AA and MRDs should undergo allo-HSCT as early as possible to optimize survival.

Original languageEnglish
Pages (from-to)1500-1508
Number of pages9
JournalBiology of Blood and Marrow Transplantation
Volume18
Issue number10
DOIs
Publication statusPublished - 2012 Oct 1

Fingerprint

Aplastic Anemia
Hematopoietic Stem Cells
Transplants
Hematopoietic Stem Cell Transplantation
Survival
Survival Analysis
Age Groups
Transplantation
Tissue Donors

Keywords

  • Allogeneic hematopoietic stem cell transplantation
  • Aplastic anemia
  • Elderly

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Allogeneic Hematopoietic Stem Cell Transplant for Adults over 40 Years Old with Acquired Aplastic Anemia. / Kim, Hawk; Lee, Kyoo Hyung; Yoon, Sung Soo; Sohn, Sang Kyun; Joo, Young Don; Kim, Sung Hyun; Kim, Byung Soo; Choi, Jung Hye; Kwak, Jae Youg; Hyun, Myung Soo; Bae, Sung Hwa; Shin, Ho Jin; Won, Jong Ho; Oh, Sukjoong; Lee, Won Sik; Park, Jae Hoo; Jung, Chul Won.

In: Biology of Blood and Marrow Transplantation, Vol. 18, No. 10, 01.10.2012, p. 1500-1508.

Research output: Contribution to journalArticle

Kim, H, Lee, KH, Yoon, SS, Sohn, SK, Joo, YD, Kim, SH, Kim, BS, Choi, JH, Kwak, JY, Hyun, MS, Bae, SH, Shin, HJ, Won, JH, Oh, S, Lee, WS, Park, JH & Jung, CW 2012, 'Allogeneic Hematopoietic Stem Cell Transplant for Adults over 40 Years Old with Acquired Aplastic Anemia', Biology of Blood and Marrow Transplantation, vol. 18, no. 10, pp. 1500-1508. https://doi.org/10.1016/j.bbmt.2012.03.015
Kim, Hawk ; Lee, Kyoo Hyung ; Yoon, Sung Soo ; Sohn, Sang Kyun ; Joo, Young Don ; Kim, Sung Hyun ; Kim, Byung Soo ; Choi, Jung Hye ; Kwak, Jae Youg ; Hyun, Myung Soo ; Bae, Sung Hwa ; Shin, Ho Jin ; Won, Jong Ho ; Oh, Sukjoong ; Lee, Won Sik ; Park, Jae Hoo ; Jung, Chul Won. / Allogeneic Hematopoietic Stem Cell Transplant for Adults over 40 Years Old with Acquired Aplastic Anemia. In: Biology of Blood and Marrow Transplantation. 2012 ; Vol. 18, No. 10. pp. 1500-1508.
@article{0c1d7e8a66f443ea853bb87ccd5cb582,
title = "Allogeneic Hematopoietic Stem Cell Transplant for Adults over 40 Years Old with Acquired Aplastic Anemia",
abstract = "Although younger age is associated with favorable prognosis in adults undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) for aplastic anemia (AA), other pretransplantation factors may be more important than age. We retrospectively analyzed the impact of older age on transplantation outcomes and survival in a total of 225 adult patients with AA who underwent allo-HSCT: 57 patients >40 years old (older patient group [OPG]) and 168 patients ≤40 years old (younger patient group [YPG]). Age at allo-HSCT ≤40 years, time from diagnosis to allo-HSCT ≤6 months, and matched related donor (MRD) were favorable prognostic factors in all study patients. Risk analysis of survival in the OPG showed that age >50 years was the only poor prognostic factor. Survival did not differ significantly between the YPG and patients <50 years old in the OPG. In conclusion, patients between the ages of 41 and 50 years with severe AA and MRDs should undergo allo-HSCT as early as possible to optimize survival.",
keywords = "Allogeneic hematopoietic stem cell transplantation, Aplastic anemia, Elderly",
author = "Hawk Kim and Lee, {Kyoo Hyung} and Yoon, {Sung Soo} and Sohn, {Sang Kyun} and Joo, {Young Don} and Kim, {Sung Hyun} and Kim, {Byung Soo} and Choi, {Jung Hye} and Kwak, {Jae Youg} and Hyun, {Myung Soo} and Bae, {Sung Hwa} and Shin, {Ho Jin} and Won, {Jong Ho} and Sukjoong Oh and Lee, {Won Sik} and Park, {Jae Hoo} and Jung, {Chul Won}",
year = "2012",
month = "10",
day = "1",
doi = "10.1016/j.bbmt.2012.03.015",
language = "English",
volume = "18",
pages = "1500--1508",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Allogeneic Hematopoietic Stem Cell Transplant for Adults over 40 Years Old with Acquired Aplastic Anemia

AU - Kim, Hawk

AU - Lee, Kyoo Hyung

AU - Yoon, Sung Soo

AU - Sohn, Sang Kyun

AU - Joo, Young Don

AU - Kim, Sung Hyun

AU - Kim, Byung Soo

AU - Choi, Jung Hye

AU - Kwak, Jae Youg

AU - Hyun, Myung Soo

AU - Bae, Sung Hwa

AU - Shin, Ho Jin

AU - Won, Jong Ho

AU - Oh, Sukjoong

AU - Lee, Won Sik

AU - Park, Jae Hoo

AU - Jung, Chul Won

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Although younger age is associated with favorable prognosis in adults undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) for aplastic anemia (AA), other pretransplantation factors may be more important than age. We retrospectively analyzed the impact of older age on transplantation outcomes and survival in a total of 225 adult patients with AA who underwent allo-HSCT: 57 patients >40 years old (older patient group [OPG]) and 168 patients ≤40 years old (younger patient group [YPG]). Age at allo-HSCT ≤40 years, time from diagnosis to allo-HSCT ≤6 months, and matched related donor (MRD) were favorable prognostic factors in all study patients. Risk analysis of survival in the OPG showed that age >50 years was the only poor prognostic factor. Survival did not differ significantly between the YPG and patients <50 years old in the OPG. In conclusion, patients between the ages of 41 and 50 years with severe AA and MRDs should undergo allo-HSCT as early as possible to optimize survival.

AB - Although younger age is associated with favorable prognosis in adults undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) for aplastic anemia (AA), other pretransplantation factors may be more important than age. We retrospectively analyzed the impact of older age on transplantation outcomes and survival in a total of 225 adult patients with AA who underwent allo-HSCT: 57 patients >40 years old (older patient group [OPG]) and 168 patients ≤40 years old (younger patient group [YPG]). Age at allo-HSCT ≤40 years, time from diagnosis to allo-HSCT ≤6 months, and matched related donor (MRD) were favorable prognostic factors in all study patients. Risk analysis of survival in the OPG showed that age >50 years was the only poor prognostic factor. Survival did not differ significantly between the YPG and patients <50 years old in the OPG. In conclusion, patients between the ages of 41 and 50 years with severe AA and MRDs should undergo allo-HSCT as early as possible to optimize survival.

KW - Allogeneic hematopoietic stem cell transplantation

KW - Aplastic anemia

KW - Elderly

UR - http://www.scopus.com/inward/record.url?scp=84866172587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866172587&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2012.03.015

DO - 10.1016/j.bbmt.2012.03.015

M3 - Article

VL - 18

SP - 1500

EP - 1508

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 10

ER -